Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Drygin

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2016
The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate CancerRichard J Rebello, Eric Kusnadi, Donald P Cameron, et al.
Cancer Research|December 17, 2010
Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growthDenis Drygin, Amy Lin, Josh Bliesath, et al.
Cancer Discovery|October 23, 2015
Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven LymphomaJennifer R Devlin, Katherine M Hannan, Nadine Hein, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer TherapeuticsMustapha Haddach, Michael K Schwaebe, Jerome Michaux, et al.
Oncotarget|July 9, 2016
Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signalingJaclyn Quin, Keefe T Chan, Jennifer R Devlin, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases InhibitorMustapha Haddach, Jerome Michaux, Michael K Schwaebe, et al.
Nature Communications|November 28, 2025
The nucleobase guanine at the 3'-terminus of oligonucleotide RGLS4326 drives off-target AMPAR inhibition and CNS toxicityTania Valencia, Laura Y Yen, Cindy Berman, et al.
Cancer Cell|July 14, 2012
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53Megan J Bywater, Gretchen Poortinga, Elaine Sanij, et al.
Molecular and Cellular Biochemistry|July 15, 2011
Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancerFabrice Pierre, Peter C Chua, Sean E O'Brien, et al.
Journal of Medicinal Chemistry|December 23, 2010
Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancerFabrice Pierre, Peter C Chua, Sean E O'Brien, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2016
The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate CancerRichard J Rebello, Eric Kusnadi, Donald P Cameron, et al.
Cancer Research|December 17, 2010
Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growthDenis Drygin, Amy Lin, Josh Bliesath, et al.
Cancer Discovery|October 23, 2015
Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven LymphomaJennifer R Devlin, Katherine M Hannan, Nadine Hein, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer TherapeuticsMustapha Haddach, Michael K Schwaebe, Jerome Michaux, et al.
Oncotarget|July 9, 2016
Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signalingJaclyn Quin, Keefe T Chan, Jennifer R Devlin, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases InhibitorMustapha Haddach, Jerome Michaux, Michael K Schwaebe, et al.
Nature Communications|November 28, 2025
The nucleobase guanine at the 3'-terminus of oligonucleotide RGLS4326 drives off-target AMPAR inhibition and CNS toxicityTania Valencia, Laura Y Yen, Cindy Berman, et al.
Cancer Cell|July 14, 2012
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53Megan J Bywater, Gretchen Poortinga, Elaine Sanij, et al.
Molecular and Cellular Biochemistry|July 15, 2011
Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancerFabrice Pierre, Peter C Chua, Sean E O'Brien, et al.
Journal of Medicinal Chemistry|December 23, 2010
Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancerFabrice Pierre, Peter C Chua, Sean E O'Brien, et al.
Pageof 4